Promising Early Launch Metrics for AbbVie's Rinvoq (upadacitinib) to Help JAK Inhibitors Solidify Their Position as Second-Line Leaders in Rheumatoid Arthritis, According to Spherix Global Insights
Retrieved on:
Monday, December 16, 2019
By comparison, Olumiant and Kevzara garnered a user-base of only 4% and 25%, respectively, at a similar time period post-launch.
Key Points:
- By comparison, Olumiant and Kevzara garnered a user-base of only 4% and 25%, respectively, at a similar time period post-launch.
- Other brands anticipated to grow include Kevzara and Olumiant (though to a much lesser extent), while Xeljanz remains relatively flat.
- With Rinvoq out of the pipeline picture, rheumatologists are more likely to prefer Gilead/Galapagos' filgotinib (JAK) and Merck's evobrutinib (BTK) over other developmental agents.
- Spherix will continue to track the launch of Rinvoq over the next year.